Genmab Dirección

Dirección controles de criterios 4/4

El CEO de Genmab's es Jan van de Winkel , nombrado en Jun 2010, tiene una permanencia de 12.08 años. compensación anual total es DKK38.10M, compuesta por 20.7% salario y 79.3% primas, incluidas acciones y opciones de la empresa. posee directamente un 0.94% de las acciones de la empresa, por valor de €214.42M. La antigüedad media del equipo directivo y de la junta directiva es de 3.3 años y 5.3 años, respectivamente.

Información clave

Jan van de Winkel

Chief Executive Officer (CEO)

kr.38.1m

Compensación total

Porcentaje del salario del CEO	20.7%
Permanencia del CEO	12.1yrs
Participación del CEO	0.9%
Permanencia media de la dirección	3.3yrs
Promedio de permanencia en la Junta Directiva	5.3yrs

Actualizaciones recientes de la dirección

Recent updates

Análisis de compensación del CEO

¿Cómo ha cambiado la remuneración de Jan van de Winkel en comparación con los beneficios de Genmab?
Fecha	Compensación total	Salario	Ingresos de la empresa
Mar 31 2022	n/a	n/a	kr.2b
Dec 31 2021	kr.38m	kr.8m	kr.3b
Sep 30 2021	n/a	n/a	kr.3b
Jun 30 2021	n/a	n/a	kr.3b
Mar 31 2021	n/a	n/a	kr.6b
Dec 31 2020	kr.37m	kr.7m	kr.5b
Sep 30 2020	n/a	n/a	kr.6b
Jun 30 2020	n/a	n/a	kr.6b
Mar 31 2020	n/a	n/a	kr.2b
Dec 31 2019	kr.35m	kr.7m	kr.2b
Sep 30 2019	n/a	n/a	kr.2b
Jun 30 2019	n/a	n/a	kr.1b
Mar 31 2019	n/a	n/a	kr.1b
Dec 31 2018	kr.28m	kr.7m	kr.1b
Sep 30 2018	n/a	n/a	kr.1b
Jun 30 2018	n/a	n/a	kr.1b
Mar 31 2018	n/a	n/a	kr.1b
Dec 31 2017	kr.27m	kr.7m	kr.1b
Sep 30 2017	n/a	n/a	kr.1b
Jun 30 2017	n/a	n/a	kr.1b
Mar 31 2017	n/a	n/a	kr.1b
Dec 31 2016	kr.23m	kr.6m	kr.1b
Sep 30 2016	n/a	n/a	kr.735m
Jun 30 2016	n/a	n/a	kr.686m
Mar 31 2016	n/a	n/a	kr.535m
Dec 31 2015	kr.20m	kr.5m	kr.764m

Compensación vs. Mercado: La compensación total ($USD5.18M) de Jan está en línea con el promedio de empresas de tamaño similar en el mercado German ($USD5.59M).

Compensación vs. Ingresos: La compensación de Jan ha sido consistente con los resultados de la empresa en el último año.

CEO

Jan van de Winkel (61 yo)

12.1yrs

Permanencia

kr.38,100,000

Compensación

Dr. Jan G. J. van de Winkel, Ph D., serves as a Member of Advisory board at Thuja Capital Management B.V. Dr. van de Winkel served as a Member of Scientific Advisory Board.He is a Co-Founder of Genmab A/S...

Equipo directivo

Nombre	Posición	Permanencia	Compensación	Propiedad
Jan van de Winkel	Co-Founder	12.1yrs	kr.38.10m	0.94% DKK 214.4m
Anthony Pagano	Executive VP & CFO	2.3yrs	kr.12.40m	0.0047% DKK 1.1m
Anthony Mancini	Executive VP & COO	2.3yrs	kr.16.60m	sin datos
Judith Klimovsky	Executive VP & Chief Development Officer	5.4yrs	kr.19.80m	0.0080% DKK 1.8m
Tahamtan Ahmadi	Executive VP	1.3yrs	kr.10.90m	0.0037% DKK 841.4k
Mijke Zachariasse	Director of Protein Production & Chemist and Non-Independent Director	no data	kr.900.00k	0.00014% DKK 31.9k
Rima Nassar	VP, Head of Global Regulatory Affairs – Oncology & Non-Independent Director	no data	kr.800.00k	0.0016% DKK 362.6k
Peter Ros	Senior Director of Finance & Accounting	no data	sin datos	sin datos
Andrew Carlsen	Senior Director	no data	sin datos	sin datos
Birgitte Stephensen	Executive VP & Chief Legal Officer	12.5yrs	sin datos	sin datos
Christopher Cozic	Executive VP & Chief People Officer	no data	sin datos	sin datos
Rachel Gravesen	Executive Officer	3.3yrs	sin datos	sin datos

3.3yrs

Permanencia media

52.5yo

Promedio de edad

Equipo directivo experimentado: El equipo directivo de GE9 se considera experimentado (3.3 años antigüedad media).

Miembros de la Junta

Nombre	Posición	Permanencia	Compensación	Propiedad
Mijke Zachariasse	Director of Protein Production & Chemist and Non-Independent Director	3.3yrs	kr.900.00k	0.00014% DKK 31.9k
Rima Nassar	VP, Head of Global Regulatory Affairs – Oncology & Non-Independent Director	2.5yrs	kr.800.00k	0.0016% DKK 362.6k
Anders Pedersen	Non-Independent Director	18.7yrs	kr.1.40m	0.017% DKK 3.9m
Deirdre Connelly	Independent Chairman of the Board	5.3yrs	kr.2.40m	0.0068% DKK 1.6m
Rolf Hoffmann	Independent Director	5.3yrs	kr.1.40m	0.0045% DKK 1.0m
Pernille Erenbjerg	Independent Deputy Chairman	7.5yrs	kr.1.80m	0.0066% DKK 1.5m
Paolo Paoletti	Independent Director	7.5yrs	kr.1.30m	0.00093% DKK 212.1k
Elizabeth O'Farrell	Independent Director	less than a year	sin datos	sin datos

5.3yrs

Permanencia media

62yo

Promedio de edad

Junta con experiencia: La junta directiva de GE9 se considera experimentada (5.3 años de antigüedad promedio).

Genmab Dirección

Dirección controles de criterios 4/4

Información clave

Actualizaciones recientes de la dirección

Genmab A/S Announces Executive Changes

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

High number of new directors

Recent updates

Genmab A/S Announces New Efficacy and Safety Data from Two Ongoing Phase 1/2 Clinical Trials Evaluating Epcoritamab, A T-Cell Engaging Bispecific Antibody Administered Subcutaneously, in Adult Patients with Certain Types of Follicular Lymphoma

Genmab A/S (CPSE:GMAB) completed the acquisition of ProfoundBio, Inc.

Genmab A/S to Present New and Updated Results from Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies At the 2024 European Hematology Association (Eha) Congress

Pfizer Inc. and Genmab A/S Announce FDA Grants Full Approval for TIVDAK to Treat Recurrent or Metastatic Cervical Cancer

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S (CPSE:GMAB) entered into a definitive agreement to acquire ProfoundBio for $1.8 billion.

Genmab A/S Announces Executive Changes

Genmab A/S and AbbVie Announce U.S. Food and Drug Administration Grants Priority Review for the Supplemental Biologics License Application for Epcoritamab (Epkinly®) for Difficult-To-Treat Relapsed or Refractory Follicular Lymphoma

Genmab A/S and Pfizer, Inc. Announces Validation for Review the Marketing Authorization Application of Tivdak®?

Genmab A/S Announces Decision in Arbitration Appeal Under License Agreement with Janssen Biotech, Inc

Pfizer Inc. and Genmab A/S Announce U.S. Food and Drug Administration Accepts TIVDAK® Supplemental Biologics License Application

Genmab A/S and AbbVie Announces New Pivotal Data for Bispecific Antibody Epcoritamab (Duobody CD3xCD20) Demonstrates High Overall and Complete Responses in Patients with Hard-To-Treat Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Announces Positive Regulatory Updates for Epcoritamab (EPKINLY®?/TEPKINLY®?) for the Treatment of Relapsed/Refractory Follicular Lymphoma

Genmab A/S Revises Earnings Guidance for the Year 2023

Genmab A/S, Annual General Meeting, Mar 13, 2024

Genmab A/S to Report Q1, 2024 Results on May 02, 2024

Genmab A/S and Seagen Inc. Announce Additional Results from the Phase 3 innovaTV 301 Randomized Global Trial

Genmab A/S Announces European Commission Approval of Tepkinly(R) (epcoritamab) for Adults with Relapsed Or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Seagen Inc. and Genmab A/S Announce That Tivdak(R) (Tisotumab Vedotin-Tftv) Met Its Primary Endpoint of Improved Overall Survival in Patients with Recurrent or Metastatic Cervical Cancer Compared to Chemotherapy

Genmab A/S Revises Earning Guidance for the Year 2023

Genmab A/S Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY(R) Diffuse Large B-Cell Lymphoma

AbbVie and Genmab Announce Positive Topline Results from Phase 1/2 EPCORE™ NHL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Follicular Lymphoma (FL)

Genmab A/S Announces Epcoritamab Added to National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology for ‘B-Cell Lymphomas’

Genmab A/S Showcases Data from Comprehensive Epcoritamab Development Program in Patients Across B-Cell Lymphomas At European Hematology Association (EHA) Annual Meeting 2023

U.S. Food and Drug Administration Approves Genmab A/S’s EPKINLY (epcoritamab-bysp) as the First and Only Bispecific Antibody to Treat Adults with Relapsed or Refractory Diffuse Large B-cell Lymphoma

Genmab A/S Provides Earnings Guidance for 2023

Genmab A/S Announces Submission of Japan New Drug Application for Epcoritamab (DuoBody®-CD3xCD20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab A/S Showcases Data From Robust Development Program Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients Across a Broad Range of B-Cell Lymphomas at the 64th Annual ASH Meeting

Genmab A/S to Report Nine Months, 2023 Results on Nov 07, 2023

Genmab A/S Announces U.S. Food and Drug Administration Accepts for Priority Review Biologics License Application (Bla) for Epcoritamab (Duobody®-Cd3xcd20) for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma (Lbcl)

Genmab Provides Earnings Guidance for Year 2022

Genmab A/S Submits Biologics License Application to the U.S. Food and Drug Administration

Genmab A/S Revises Earnings Guidance for the Year 2022

Genmab A/S Submits Biologics License Application to U.S. Food and Drug Administration for Epcoritamab for the Treatment of Relapsed/Refractory Large B-Cell Lymphoma

Genmab Announces Late-Breaking Phase 2 Trial Results of Investigational Epcoritamab (DuoBody®-CD3xCD20) in Relapsed/Refractory Large B-cell Lymphoma (LBCL) Patients Presented at European Hematology Association (EHA) Presidential Symposium

Genmab A/S and Seagen Inc. Present Data from Tisotumab Vedotin (TIVDAK) Clinical Development Program and Additional Cervical Cancer Research at ASCO 2022 Annual Meeting

Genmab A/S Revises Earnings Guidance for 2022

AbbVie and Genmab Announce Topline Results for Epcoritamab (DuoBody®-CD3xCD20) from Phase 1/2 Trial in Patients with Relapsed/Refractory Large B-cell Lymphoma (LBCL)

Genmab A/S Elects Elizabeth O’Farrell to the Board of Directors

Genmab A/S Announces Appointments of Birgitte Stephensen to Chief Legal Officer and Chris Cozic to Chief People Officer

Genmab A/S Provides Earnings Guidance for the Year 2022

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Genmab A/S Announces Janssen Received Conditional European Marketing Authorization for RYBREVANT

High number of new directors

Análisis de compensación del CEO

CEO

Permanencia

Compensación

Equipo directivo

Permanencia media

Promedio de edad

Miembros de la Junta

Permanencia media

Promedio de edad